NextCure  Inc

NASDAQ NXTC

Download Data

NextCure  Inc Net Current Asset Value 2 year CAGR for the year ending December 31, 2023: -33.17%

NextCure  Inc Net Current Asset Value 2 year CAGR is -33.17% for the year ending December 31, 2023, a -23.74% change year over year. Net current asset value is a financial metric that represents the excess of a company's current assets over its total liabilities. It is calculated by subtracting the total liabilities from the total current assets of a company. Net current asset value provides insights into the value that would be available to shareholders if the company were to liquidate its current assets and pay off its liabilities. This metric is used to assess the company's liquidity position and the potential value for shareholders in a liquidation scenario. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • NextCure  Inc Net Current Asset Value for the year ending December 31, 2022 was 147,352,000.00, a -32.66% change year over year.
  • NextCure  Inc Net Current Asset Value for the year ending December 31, 2021 was 218,817,000.00, a -20.45% change year over year.
  • NextCure  Inc Net Current Asset Value for the year ending December 31, 2020 was 275,055,000.00, a -9.91% change year over year.
  • NextCure  Inc Net Current Asset Value for the year ending December 31, 2019 was 305,311,000.00, a 619.35% change year over year.
NASDAQ: NXTC

NextCure  Inc

CEO Mr. Michael S. Richman MSBA
IPO Date May 9, 2019
Location United States
Headquarters 9000 Virginia Manor Road, Beltsville, MD, United States, 20705
Employees 82
Sector Healthcare
Industry Biotechnology
Description

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

StockViz Staff

September 20, 2024

Any question? Send us an email